Allergy reactions to insulin: Effects of continuous subcutaneous insulin infusion and insulin analogues

Diabetes/Metabolism Research and Reviews

Volumn 23, Issue 5, 2007, Pages 348-355

  Radermecker, Regis P ^a   Scheen, A J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

CSII; Diabetes; Insulin allergy; Insulin analogues; Insulin hypersensitivity; Insulin pump

Indexed keywords

ANTIDIABETIC AGENT; ANTIHISTAMINIC AGENT; BOVINE INSULIN; CORTICOSTEROID; DEXAMETHASONE; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN CRYSTALLINE; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT; PIG INSULIN; RECOMBINANT HUMAN INSULIN; UNCLASSIFIED DRUG;

ANTIGENICITY; CONTINUOUS INFUSION; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DOSE INCREASE; DRUG METABOLISM; DRUG STABILITY; FEVER; HUMAN; HYPOGLYCEMIA; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE URTICARIA; INSULIN ALLERGY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; IRRITABILITY; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; SWEATING; URTICARIA;

DIABETES MELLITUS; DRUG HYPERSENSITIVITY; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS;

EID: 34447628506     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.714     Document Type: Review

References (73)

1. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 2002; 25: 593-598.
2. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care 2003; 26: 1079-1087.
3. Colquitt J, Toyle P, Waugh N. Are analogues insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis. Diabet Med 2003; 20: 863-866.
4. Radermecker RP, Scheen AJ. Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness. Diabetes Metab Res Rev 2004; 20: 178-188.
5. Hirsch IB. Insulin analogues. N Engl J Med 2005; 352: 174-183.
6. Oiknine R, Bernbaum M, Mooradian AD. A critical appraisal of the role of insulin analogues in the management of diabetes mellitus. Drugs 2005; 65: 325-340.
7. Lawrence RD. Local insulin reactions. Lancet 1925; 1: 1125-1126.
8. Vialettes B. L'allergie à l'insuline. Diabete Metab 1986; 12: 169-172.
9. Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 1993; 16(Suppl. 3): 155-165.
10. Paley RG, Tunbridge RE. Dermal reactions to insulin therapy. Diabetes 1952; 1: 22-27.
11. Arkins JA, Engoring NH, Lennon E. The incidence of skin reactivity to insulin in diabetic patients. J Allergy 1962; 33: 69-72.
12. Patterson R, Roberts M, Grammer LC. Insulin allergy; reevaluation after two decades. Ann Allergy 1990; 64: 459-462.
13. Grammer LC. Immunologic reaction to insulin and other proteins. Immunol Allergy Clin North Am 1998; 18: 809-816.
14. Richardson T, Kerr D. Skin-related complications of insulin therapy. Epidemiology and emerging management strategies. Am J Clin Dermatol 2003; 4: 661-667.
15. Sola-Gazagnes A, Pecquet C. Allergie à l'insuline en 2003. Journées de Diabéologie de l'Hôtel Dieu, Flammarion Médecine-Sciences: Paris, 2004; 161-179.
16. Ratner RE, Phillips TM, Steiner M. Persistent cutaneous insulin allergy resulting from high-molecular-weight insulin aggregates. Diabetes 1990; 39: 728-833.
17. Brange J, Owens DR, Kang S, Volund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990; 13: 923-954.
18. Ottesen JL, Nilsson P, Jami J, et al. The potential immunogenicity of human insulin and insulin analogues evaluated in a transgene mouse model. Diabetologia 1994; 37: 1178-1185.
19. JiXiong X, Jianying L, Yulan C, Huixian C. The human insulin analog aspart can induce insulin allergy. Diabetes Care 2004; 27: 2084-2085.
20. Radermecker RP, Scheen AJ. Treatment of allergy to insulin using continuous subcutaneous insulin infusion with short-acting insulin analogues. Infusystems International 2004; 3: 1-5.
21. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-2148.
22. Doyle EA, Weinzimer SA, Steffen AT, et al. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 2004; 27: 1554-1558.
23. Kahn CR, Rosenthal AS. Immunologic reactions to insulin: insulin allergy, insulin resistance, and the autoimmune insulin syndrome. Diabetes Care 1979; 2: 283-295.
24. Grammer L. Insulin allergy. Clin Rev Allergy 1986; 4: 189-200.
25. Messaad D, Outtas O, Demoly P. Hypersensibilité aux insulines. Presse Med 2004; 33: 631-638.
26. Bodtger U, Wittrup M. A rational clinical approach to suspected insulin allergy: status after five years and 22 cases. Diabet Med 2005; 22: 102-106.
27. De Shazo RD, Boehm TM, Kumar D, Galloway JA. Dermal hypersensitivity reactions to insulin: correlations of three patterns to their histopathology. J Allergy Clin Immunol 1982; 69: 229-237.
28. Silva MER, Mendes MJM, Ursich MJM, et al. Human insulin allergy-immediate and late type III reactions in a long-standing IDDM patient. Diabetes Res Clin Pract 1997; 36: 67-70.
29. Katahira M, Hara I, Nishizaki T. Insulin allergy decreased by Humulin S (Humulin R) and not by insulin aspart or Actrapid Penfill (Penfill R). Diabet Med 2005; 22: 1454-1459.
30. Lee A-Y, Chey W-Y, Choi J, Jeon J-S. Insulin-induced drug eruptions and reliability of skin tests. Acta Derm Venereol 2002; 82: 114-117.
31. Primeau M-N, Adkinson NF Jr, Hamilton RG. Natural rubber pharmaceutical vial closures release latex allergens that produce skin reactions. J Allergy Clin Immunol 2001; 107: 958-962.
32. Shojaei AR, Haas DA. Local anesthetic cartridges and latex allergy: a literature review. J Can Dent Assoc 2002; 68: 622-626.
33. Roest MA, Shaw S, Orton DI. Insulin-injection-site reactions associated with type 1 latex allergy. N Engl J Med 2003; 348: 265-266.
34. Lougheed W, Albisser AM, Martindale HM, Chow JC, Clement JR. Physical stability of insulin formulations. Diabetes 1983; 32: 424-432.
35. Chantelau E, Lange G, Gasthaus M, Boxberger M, Berger M. Interaction between plastic catheter tubings and regular insulin preparations used for continuous subcutaneous insulin-infusion therapy. Diabetes Care 1987; 10: 348-351.
36. Melberg SG, Havelund S, Villumsen J, Brange J. Insulin compatibility with polymer materials used in external pump infusion systems. Diabet Med 1988; 5: 243-247.
37. Radermecker RP, Piérard GE, Scheen AJ. Lipodystrophy Reactions to Insulin: Effects of Continuous Insulin Infusion and New Insulin Analogues. Am J Clin Dermatol (in press).
38. Grant W, de Shazo RD, Frentz J. Use of low-dose continuous corticosteroid infusion to facilitate insulin pump use in local insulin hypersensitivity. Diabetes Care 1986; 9: 318-319.
39. Gin H, Aubertin J. Generalized allergy due to zinc and protamine in insulin preparation treated with insulin pump. Diabetes Care 1987; 10: 789-790.
40. Valentini U, Cimino A, Rocca L, Pelizzari R, Rotondi A, Tosoni C. CSII in management of insulin allergy. Diabetes Care 1988; 11: 97-98.
41. Nagai T, Nagai Y, Tomizawa T, Mori M. Immediate-type human insulin allergy successfully treated by continuous subcutaneous insulin infusion. Intern Med 1997; 36: 575-578.
42. Fineberg NS, Fineberg SG, Anderson JH, Birkett MA, Gibson RG, Hufferd S. Immunologic effects of insulin lispro [(Lys (B28), Pro (B29) human insulin)] in IDDM and NIDDM patients previously treated with insulin. Diabetes 1996; 45: 1750-1754.
43. Fineberg SE, Huang J, Brunelle R, Gulliya KS, Anderson JH Jr. Effect of long-term exposure to insulin lispro on the induction of antibody response in patients with type 1 or type 2 diabetes. Diabetes Care 2003; 26: 89-96.
44. Lindholm A, Jensen LB, Home PD, Raskin P, Boehm BO, Rastam J. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care 2002; 25: 876-882.
45. Kumar D. Lispro analog for treatment of generalized allergy to human insulin. Diabetes Care 1997; 20: 1357-1359.
46. Abraham MR, Al-Sharafi BA, Saavedra GA, Khardori R. Lispro in the treatment of insulin allergy. Diabetes Care 1999; 22: 1916-1917.
47. Lluch-Bernal M, Fernandez M, Herrera-Pombo JL, Sastre J. Insulin lispro, an alternative in insulin hypersensitivity. Allergy 1999; 54: 186-187.
48. Panczei P, Hosszufalusi N, Horvath MM, Horvath A. Advantage of insulin lispro in suspected insulin allergy. Allergy 2000; 55: 418-419.
49. Adachi A, Fukunaga A, Horikawa T. A case of human insulin allergy induced by short-acting and intermediate-acting insulin but not by long-acting insulin. Int J Dermatol 2004; 43: 597-599.
50. Airaghi L, Lorini M, Tedeschi A. The insulin analog aspart: a safe alternative in insulin allergy. Diabetes Care 2001; 24: 2000.
51. Yasuda H, Nagata M, Moriyama H, et al. Human insulin analog insulin aspart does not cause insulin allergy. Diabetes Care 2001; 24: 2008-2009.
52. Kara C, Kutlu AO, Evliyaoglu O, Bilgili H, Yildirim N. Successful treatment of insulin allergy in a 1-year-old infant with neonatal diabetes by lispro and glargine insulin. Diabetes Care 2005; 28: 983-984.
53. Hermoso F, Vazquez M, Chaves G, Reviriego J, Andion R. Generalized allergy to human insulin treated with insulin lispro (Abstract). Diabetologia 1997; 40(Suppl. 1): A349.
54. Barranco R, Herrero T, Tomero P, et al. Systemic allergic reaction by a human insulin analog. Allergy 2003; 58: 536.
55. Yokoyama H, Fukumoto S, Koyama H, Emoto M, Kitagawa Y, Nishizawa Y. Insulin allergy; desensitization with crystalline zinc-insulin and steroid tapering. Diabetes Res Clin Pract 2003; 61: 161-166.
56. Mizuhashi S, Nakamura K, Mori Y, Noda M, Nakanishi K. Insulin allergy and immunologic insulin resistance caused by interleukin-6 in a patient with lung cancer. Diabetes Care 2006; 29: 1711-1712.
57. Castera V, Dutour-Meyer A, Koeppel M, Petijean C, Darmon P. Systemic allergy to human insulin and its rapid and long acting analogs: successful treatment by continuous subcutaneous insulin lispro infusion. Diabetes Metab 2005; 31: 391-400.
58. Takata H, Kumon Y, Osaki F, et al. The human insulin analogue aspart is not the almighty solution for insulin allergy. Diabetes Care 2003; 26: 253-254.
59. Frigerio G, Aubry M, Gomez F, et al. Desensitization-resistant insulin allergy. Allergy 1997; 52: 238-239.
60. B32) insulin glargine (HOE901) resolves a generalized allergy to human insulin in type 1 diabetes. Diabetes Care 2001; 24: 411-412.
61. Durand-Gonzalez KN, Guillausseau N, Pecquet G, Gayno JP. Glargine insulin is not an alternative in insulin allergy. Diabetes Care 2003; 26: 2216.
62. Vernassiére G, Tréchot P, Guerci B, Commun N, Schmutz JL, Barbaud A. Deux premiers cas de sensibilisation retardée aux insulines humaines recombinantes modifiées (Abstract). Ann Dermatol Venereol 2004; 13: P1.
63. Moyes V, Driver R, Groom A, Mirakian R, Chowdhury TA. Insulin allergy in a patient with Type 2 diabetes successfully treated with continuous subcutaneous insulin infusion. Diabet Med 2006; 23: 204-206.
64. Darmon P, Castera V, Koeppel M-C, Petitjean C, Dutour A. Type III allergy to insulin detemir. Diabetes Care 2005; 28: 2980.
65. Lougheed WD, Zinman B, Strack TR, et al. Stability of insulin Lispro in insulin infusion systems. Diabetes Care 1997; 20: 1061-1065.
66. Defelippis MR, Bell MA, Heyob JA, Storms SM. In vitro stability of insulin lispro in continuous subcutaneous insulin infusion. Diabetes Technol Ther 2006; 8: 358-368.
67. Eapen SS, Connor EL, Gern JE. Insulin desensitisation with insulin lispro and an insulin pump in a 5-year-old child. Ann Allergy Asthma Immunol 2000; 85: 395-397.
68. Pratt EJ, Miles P, Kerr D. Localized insulin allergy treated with continuous subcutaneous insulin. Diabet Med 2001; 18: 514-516.
69. Näf S, Esmatjes E, Recasens M, et al. Continuous subcutaneous insulin infusion to resolve an allergy to human insulin. Diabetes Care 2002; 25: 634-635.
70. Durand-Gonzalez KN, Guillausseau N, Anciaux ML, Hentschel V, Gayno JP. Allergy to insulin in a woman with gestational diabetes mellitus: transient efficiency of continuous subcutaneous insulin lispro infusion. Diabetes Metab 2003; 29: 432-434.
71. Sola-Gazagnes A, Pecquet C, Radermecker R, et al. Successful treatment of insulin allergy in a type 1 diabetic patient by means of constant subcutaneous pump infusion of insulin. Diabetes Care 2003; 26: 2961-2962.
72. Imiela A, Tavernier J-Y, Carotte-Lefebvre I, Deverny F, Delaporte E, Lamblin C. Allergie à l'insuline humaine recombinante: à propos de 3 cas avec manifestations immédiates généralisées. Rev Franc Allergol Immunol Clin 2003; 43: 165-169.
73. Matheu V, Perez E, Hernandez M, et al. Insulin allergy and resistance successfully treated by desensitisation with Aspart insulin. Clin Mol Allergy 2005; 3: 16, Doi:10.1186/1476-7961-3-16.